

CERTIFICATE OF MAILING



08/04/97

I hereby certify that this paper and every paper referred to therein as being enclosed is being deposited with the U.S. Postal Service as first class mail, postage prepaid, in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on August 1, 1997 (Date of Deposit)

Date

Name

1010/16104-US4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Howard L. WEINER et al.

Serial No: 08/279,275

Group Art Unit: 1818

Filed: July 22, 1994

Examiner: P. Achutamurthy

For: **TREATMENT OF AUTOIMMUNE DISEASE BY ORAL ADMINISTRATION
OF AUTOANTIGENS**

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

RECEIVED
AUG 26 1997
1800

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In order to comply with discretionary regulations 37 CFR §§ 1.97 and 1.98, attached hereto is Form PTO-1449, and a copy¹ of the document listed thereon.

The document is a press release issued by AutoImmune Inc., the assignee of the present application, on May 12, 1997 stating "AutoImmune Inc. today announced preliminary results from two Phase II trials of Colloral® for rheumatoid arthritis. Both trials


¹To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the file of a parent application. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited, then none is known to the undersigned.

demonstrated positive trends for Colloral, although statistical significance was not demonstrated versus placebo." "Colloral" is type II collagen. These results are consistent with the broad applicability of the present invention in treating T-cell mediated autoimmune disease.

This Information Disclosure Statement should be considered by the Office under 37 CFR § 1.97(c). A petition under 37 CFR § 1.97(d)(2) and a certification under 37 CFR § 1.97(e) accompany this paper.

The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider any of the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Respectfully submitted,



Seth H. Jacobs
Registration No. 32,140
Attorney for Applicants

DARBY & DARBY P.C.
805 Third Avenue
New York, N.Y. 10022
(212) 527-7700